Olmesartán Aurovitas (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olmesartán Aurovitas, is an angiotensin II receptor blocker presented as a tablet for oral use. It is employed in the management of hypertension in adult patients. GNH USA supplies Olmesartán Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartán Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxomil is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower blood pressure.

- Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diastolic heart failure: assists in decreasing afterload and improving symptoms. - Chronic kidney disease with proteinuria: slows progression by lowering intraglomerular pressure.

Adverse reactions to olmesartan are generally mild to moderate and vary among individuals.

Common Side Effects: - Dizziness: especially after the first dose or when standing quickly. - Headache: mild to moderate intensity. - Fatigue: feeling of tiredness without exertion. - Nasal congestion: mild blockage of the nasal passages. - Diarrhea: loose, watery stools. - Cough: non‑productive cough.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat that may compromise breathing. - Hyperkalemia: elevated potassium levels that can affect heart rhythm. - Acute kidney injury: sudden decline in renal function. - Severe hypotension: markedly low blood pressure causing faintness or shock. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress. - Allergic rash: widespread skin eruption with itching or hives.

When using olmesartan, clinicians should assess patient history and monitor relevant parameters.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function: evaluate serum creatinine and eGFR before initiation and during therapy. - Electrolyte balance: monitor potassium levels, especially if combined with potassium‑sparing agents. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Drug interactions: review concomitant medications for potential additive hypotensive effects. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan may interact with several medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid): - Aliskiren: combined use in diabetic patients can increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics: may cause dangerous elevations in serum potassium. - Lithium: concurrent use can raise lithium concentrations and risk toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - ACE inhibitors: additive blood‑pressure lowering effect; monitor for hypotension. - Thiazide diuretics: can enhance antihypertensive response and increase risk of electrolyte disturbances.